Hypertension treatment devices maker Kona Medical closed a Series C funding round totaling $40 million in support of its ultrasound-based renal ablation systems.
Unlike other renal ablation systems, Kona’s Surround Sound device uses external ultrasound to non-invasively target the nerves leading to and from the kidney, according to a press release.
"The fully non-invasive system the company is developing may greatly expand access to renal denervation therapy and offer a more patient-friendly alternative for the tens of millions of people who suffer from drug-resistant hypertension," according to a press release.
Funding for the company, which is headquartered bi-coastally in Bellevue, Wash., and Menlo Park, Calif., included new large-cap strategic investors alongside prior funders, Kona noted.
The new financing round brings the total for the year to $70 million, following the $30 million series C the company closed in May.
"We greatly appreciate the interest and support shown by leading healthcare companies and investors," Kona founder & CEO Dr. Michael Gertner said in prepared remarks. "The resources provided by this financing will advance our mission to offer a treatment alternative for the millions of people who suffer from resistant hypertension."
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.